NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Mankind Pharma Limited (NSE: MANKIND)
MANKIND Technical Analysis
4
As on 17th Apr 2025 MANKIND SHARE Price closed @ 2581.60 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2419.50 & Strong Buy for SHORT-TERM with Stoploss of 2380.03 we also expect STOCK to react on Following IMPORTANT LEVELS. |
MANKINDSHARE Price
Open | 2509.90 | Change | Price | % |
High | 2600.00 | 1 Day | 61.60 | 2.44 |
Low | 2500.00 | 1 Week | 267.65 | 11.57 |
Close | 2581.60 | 1 Month | 410.65 | 18.92 |
Volume | 489420 | 1 Year | 300.55 | 13.18 |
52 Week High 2792.55 | 52 Week Low 1322.65 |
NSE INDIA Most Active Stocks
IDEA | 7.31 | 0.55% |
IDFCFIRSTB | 63.00 | -0.51% |
YESBANK | 18.09 | 1.23% |
TATASTEEL | 137.14 | 0.12% |
GTLINFRA | 1.49 | 0.00% |
VIKASLIFE | 2.59 | -9.44% |
WIPRO | 236.90 | -4.34% |
SUZLON | 55.07 | 1.34% |
NBCC | 98.40 | 2.71% |
UJJIVANSFB | 42.10 | 7.12% |
NSE INDIA Top Gainers Stocks
NSE INDIA Top Losers Stocks
VIKASLIFE | 2.59 | -9.44% |
ROML | 50.49 | -6.78% |
ROSSELLIND | 77.66 | -6.14% |
DYNPRO | 291.00 | -6.08% |
SONATSOFTW | 314.70 | -6.07% |
TREJHARA | 232.28 | -5.81% |
GATECHDVR | 1.05 | -5.41% |
MGEL | 14.23 | -5.26% |
KESORAMIND | 3.15 | -5.12% |
MAHAPEXLTD | 119.14 | -5.09% |
MANKIND Daily Charts |
MANKIND Intraday Charts |
Whats New @ Bazaartrend |
MANKIND Free Analysis |
|
MANKIND Important Levels Intraday
RESISTANCE | 2774.30 |
RESISTANCE | 2712.50 |
RESISTANCE | 2674.30 |
RESISTANCE | 2636.10 |
SUPPORT | 2527.10 |
SUPPORT | 2488.90 |
SUPPORT | 2450.70 |
SUPPORT | 2388.90 |
MANKIND Target April 2025
4th UP Target | 3315.19 |
3rd UP Target | 2986.6 |
2nd UP Target | 2783.49 |
1st UP Target | 2580.38 |
1st DOWN Target | 2000.82 |
2nd DOWN Target | 1797.71 |
3rd DOWN Target | 1594.6 |
4th DOWN Target | 1266.01 |
MANKIND Weekly Target
4th UP Target | 2807.68 |
3rd UP Target | 2661.06 |
2nd UP Target | 2570.43 |
1st UP Target | 2479.80 |
1st DOWN Target | 2221.20 |
2nd DOWN Target | 2130.57 |
3rd DOWN Target | 2039.94 |
4th DOWN Target | 1893.32 |
MANKIND Target2025
4th UP Target | 5523.76 |
3rd UP Target | 4676.02 |
2nd UP Target | 4152.01 |
1st UP Target | 3628 |
1st DOWN Target | 2132.8 |
2nd DOWN Target | 1608.79 |
3rd DOWN Target | 1084.78 |
4th DOWN Target | 237.04 |
Mankind Pharma Limited ( NSE INDIA Symbol : MANKIND )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
MANKIND Synopsis Technicals View
50 Day EMA |
N/A (Short Term) |
N/A | |
100 Day EMA | N/A (Mid Term) | N/A | |
200 Day EMA | N/A (Long Term) | N/A | |
MACD (12 26 9) | N/A | N/A | |
RSI (14) | N/A | N/A | |
MFI (14) | N/A | N/A | |
CCI (20) | N/A | N/A | |
WILLIAM %R (14) | N/A | N/A | |
ADX (14) | N/A | N/A | |
PSAR | N/A | N/A | |
10 Day Avg Volume | N/A |
MANKIND Other Details
Segment | EQ | |
Market Capital | 0.00 | |
Sector | ||
Industry | ||
Offical website | > echo $website ; ?> |
MANKIND Address
![]() |
MANKIND Latest News
MANKIND Business Profile
N/A
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service